Corcept Therapeutics reported that its ovarian-cancer drug LIFYORLI generated $47.6 million [1] during its first full quarter after FDA approval.
The strong initial performance of the drug suggests it could become a "blockbuster" product, though financial analysts said the company's current market valuation already reflects this expectation [1].
In an earnings release on April 30, 2026 [6], the company reported total revenue for the first quarter of 2026 at $164.9 million [4]. This represents an increase from the $157.2 million [5] reported during the same quarter a year earlier [4].
Management has set an ambitious target for the drug's performance in the U.S. market, projecting peak revenue to exceed $1 billion [2]. This growth is driven by robust clinical demand and a successful launch phase for the treatment [1].
Beyond the U.S. market, the global net present value of LIFYORLI is estimated at $4 billion [3]. The company continues to guide its financial expectations higher as the drug gains traction in the oncology sector [4].
“LIFYORLI generated $47.6 million in its first full quarter”
The rapid revenue growth of LIFYORLI validates the clinical demand for new ovarian-cancer treatments. However, the gap between the drug's actual performance and the company's stock valuation indicates that investors have already priced in the drug's success, leaving less room for further price appreciation unless the company exceeds its already high peak-revenue targets.
